Stockscreener 앱 받기
22.51
11.38%
-2.89
전일 마감가:
$25.40
열려 있는:
$25.79
하루 거래량:
30,777
Relative Volume:
36.49
시가총액:
$782.20M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.21%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$22.50
$26.80
1주일 범위
$22.50
$26.80
52주 변동 폭
$19.00
$26.80
First Tracks Biotherapeutics Inc Stock (TRAXV) Company Profile
Compare TRAXV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAXV
First Tracks Biotherapeutics Inc
|
22.51 | 782.20M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
First Tracks Biotherapeutics Inc 주식(TRAXV)의 최신 뉴스
TRAXV|TRAXV.NB|Price:24.550| - TradingKey
First Tracks Biotherapeutics, Inc. (TRAXV) - Minichart
TRAXV Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback - MSN
TRAXV: Static price chart | First Tracks Biotherapeutics, Inc. | US3371851029 - marketscreener.com
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Market Today: JPM's Dimon warns; UAL hikes fees; NBIX buys SLNO - GuruFocus
Spin-off Imminent At AnaptysBio - San Diego Business Journal
symbol__ Stock Quote Price and Forecast - CNN
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 - Investing.com
ANAPTYSBIO (ANAB) reports ownership of 100 First Tracks Biotherapeutics shares - Stock Titan
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement - marketscreener.com
AnaptysBio authorizes $100M stock buyback, plans spin-off By Investing.com - Investing.com Australia
AnaptysBio appoints Susannah Gray to board; Dennis Mulroy and Eric Loumeau to Separate - TradingView — Track All Markets
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - Sahm
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible - Yahoo Finance
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress - Yahoo Finance
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma - Yahoo Finance
Press Release Service: Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy - CRISPR Medicine News
Fresh Tracks to cease stock trading as drug company dissolves - BizWest
Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market - Yahoo Finance
Fresh Tracks expects to distribute $5M to $7M to shareholders after dissolution - Daily Camera
Cash-strapped Fresh Tracks pauses R&D run as search for a buyer continues - Fierce Biotech
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix - Yahoo Finance
Excision BioTherapeutics receives FDA Fast Track designation for EBT-101, a first-in-class CRISPR-based gene therapy candidate to functionally cure HIV-1 - European AIDS Treatment Group
Fresh Tracks may disappear as biotech mulls sale to continue autoimmune pipeline - Fierce Biotech
Fresh Tracks Therapeutics (FRTX) Stock Price, News & Analysis $FRTX - MarketBeat
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics - GlobeNewswire
First Tracks Biotherapeutics Inc (TRAXV) 재무 분석
First Tracks Biotherapeutics Inc (TRAXV)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.19%
0.43%
자본화:
|
볼륨(24시간):